• 1
    Reya T,Morrison SJ,Clarke MF,Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105111.
  • 2
    Hart LS,El-Deiry WS. Invincible, but not invisible: Imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol 2008; 26: 29012910.
  • 3
    Visvader JE,Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755768.
  • 4
    Schatton T,Murphy GF,Frank NY,Yamaura K,Waaga-Gasser AM,Gasser M,Zhan Q,Jordan S,Duncan LM,Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature 2008; 451: 345349.
  • 5
    Hughes OR,Stewart R,Dimmick I,Jones EA. A critical appraisal of factors affecting the accuracy of results obtained when using flow cytometry in stem cell investigations: Where do you put your gates? Cytometry Part A 2009; 75A: 803810.
  • 6
    Doyle LA,Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 73407358.
  • 7
    Nakanishi T,Doyle LA,Hassel B,Wei Y,Bauer KS,Wu S,Pumplin DW,Fang HB,Ross DD. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 2003; 64: 14521462.
  • 8
    Rabindran SK,Ross DD,Doyle LA,Yang W,Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60: 4750.
  • 9
    Ross DD,Doyle LA. Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 2004; 6: 105107.
  • 10
    Goodell MA,McKinney-Freeman S,Camargo FD. Isolation and characterization of side population cells. Methods Mol Biol 2005; 290: 343352.
  • 11
    Hirschmann-Jax C,Foster AE,Wulf GG,Goodell MA,Brenner MK. A distinct “side population” of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle 2005; 4: 203205.
  • 12
    Srivastava VK,Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry Part A 2008; 73A: 940948.
  • 13
    Benchaouir R,Picot J,Greppo N,Rameau P,Stockholm D,Garcia L,Paldi A,Laplace-Builhe C. Combination of quantification and observation methods for study of “Side Population” cells in their “in vitro” microenvironment. Cytometry Part A 2007; 71A: 251257.
  • 14
    Smith PJ,Nakeff A,Watson JV. Flow-cytometric detection of changes in the fluorescence emission spectrum of a vital DNA-specific dye in human tumour cells. Exp Cell Res 1985; 159: 3746.
  • 15
    Durand RE,Olive PL. Cytotoxicity, Mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem 1982; 30: 111116.
  • 16
    Chen AY,Yu C,Gatto B,Liu LF. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993; 90: 81318135.
  • 17
    Sunavala-Dossabhoy G,Van Dyke MW. Combinatorial identification of a novel consensus sequence for the covalent DNA-binding polyamide tallimustine. Biochemistry 2005; 44: 25102522.
  • 18
    Jonker JW,Freeman J,Bolscher E,Musters S,Alvi AJ,Titley I,Schinkel AH,Dale TC. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005; 23: 10591065.
  • 19
    Ho MM,Ng AV,Lam S,Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 48274833.
  • 20
    Sung JM,Cho HJ,Yi H,Lee CH,Kim HS,Kim DK,Abd El-Aty AM,Kim JS,Landowski CP,Hediger MA, Shin HC. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008; 371: 163167.
  • 21
    Patrawala L,Calhoun T,Schneider-Broussard R,Zhou J,Claypool K,Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 62076219.
  • 22
    Polgar O,Robey RW,Bates SE. ABCG2: Structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008; 4: 115.
  • 23
    Robey RW,Polgar O,Deeken J,To KW,Bates SE. ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26: 3957.
  • 24
    Schellens JH,Maliepaard M,Scheper RJ,Scheffer GL,Jonker JW,Smit JW,Beijnen JH,Schinkel AH. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 2000; 922: 188194.
  • 25
    Koster DA,Palle K,Bot ES,Bjornsti MA,Dekker NH. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007; 448: 213217.
  • 26
    Pommier Y. Camptothecins and topoisomerase I: A foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: Importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 2004; 4: 429434.
  • 27
    Cheung SY,Evans ND,Chappell MJ,Godfrey KR,Smith PJ,Errington RJ. Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling. Math Biosci 2008; 213: 119134.
  • 28
    Debenham PG,Webb MB. Dominant mutation in mouse cells associated with resistance to Hoechst 33258 dye, but sensitivity to ultraviolet light and DNA base-damaging compounds. Somat Cell Mol Genet 1987; 13: 2132.
  • 29
    Smith PJ,Lacy M,Debenham PG,Watson JV. A mammalian cell mutant with enhanced capacity to dissociate a bis-benzimidazole dye-DNA complex. Carcinogenesis 1988; 9: 485490.
  • 30
    Gryczynski I,Gryczynski Z,Lakowicz JR,Yang D,Burke TG. Fluorescence spectral properties of the anticancer drug topotecan by steady-state and frequency domain fluorometry with one-photon and multi-photon excitation. Photochem Photobiol 1999; 69: 421428.
  • 31
    Khan QA,Pilch DS. Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J Mol Biol 2007; 365: 561569.
  • 32
    Kit S,Dubbs DR,Piekarski LJ,Hsu TC. Deletion of thymidine kinase activity from L cells resistant to bromodeoxyuridine. Exp Cell Res 1963; 31: 297312.
  • 33
    Smith PJ,Bell SM,Dee A,Sykes H. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: Ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons. Carcinogenesis 1990; 11: 659665.
  • 34
    Smith PJ,Debenham PG,Watson JV. A role of DNA topoisomerases in the active dissociation of DNA minor groove-ligand complexes. A flow cytometric study of inhibitor effects. Mutat Res 1989; 217: 163172.
  • 35
    Rowe TC,Chen GL,Hsiang YH,Liu LF. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 1986; 46(4 Part 2): 20212026.
  • 36
    Feeney GP,Errington RJ,Wiltshire M,Marquez N,Chappell SC,Smith PJ. Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer 2003; 88: 13101317.
  • 37
    Bowlin TL,McKown BJ,Sunkara PS. Ornithine decarboxylase induction and polyamine biosynthesis are required for the growth of interleukin-2- and interleukin-3-dependent cell lines. Cell Immunol 1986; 98: 341350.
  • 38
    Seiler N,Bolkenius FN,Knodgen B,Haegele K. The determination of N1-acetylspermine in mouse liver. Biochim Biophys Acta 1981; 676: 17.
  • 39
    Smith PJ,Blunt N,Wiltshire M,Hoy T,Teesdale-Spittle P,Craven MR,Watson JV,Amos WB,Errington RJ,Patterson LH. Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopy. Cytometry 2000; 40: 280291.
  • 40
    Watson JV,Nakeff A,Chambers SH,Smith PJ. Flow cytometric fluorescence emission spectrum analysis of Hoechst-33342-stained DNA in chicken thymocytes. Cytometry 1985; 6: 310315.
  • 41
    Errington RJ,Ameer-Beg SM,Vojnovic B,Patterson LH,Zloh M,Smith PJ. Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells. Adv Drug Deliv Rev 2005; 57: 153167.
  • 42
    Chomczynski P,Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156159.
  • 43
    Davis SK,Bardeen CJ. Cross-linking of histone proteins to DNA by UV illumination of chromatin stained with Hoechst 33342. Photochem Photobiol 2003; 77: 675679.
  • 44
    Snyder RD,Vogelpohl SJ,Baldwin BL,Deaton ED,Baden E,Carter JH. Apparent inhibition of apoptosis by polyamines and aminothiols in DNA fragmentation assays is artifactual. Cell Death Differ 1996; 3: 323330.
  • 45
    Fontana M,Lestingi M,Mondello C,Braghetti A,Montecucco A,Ciarrocchi G. DNA binding properties of FCE24517, an electrophilic distamycin analogue. Anticancer Drug Des 1992; 7: 131141.
  • 46
    Evans ND,Errington RJ,Shelley M,Feeney GP,Chapman MJ,Godfrey KR,Smith PJ,Chappell MJ. A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. Math Biosci 2004; 189: 185217.
  • 47
    Magni M,Shammah S,Schiro R,Mellado W,Dalla-Favera R,Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87: 10971103.
  • 48
    Bracht K,Liebeke M,Ritter CA,Grunert R,Bednarski PJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: Comparison with the national cancer institute data. Anticancer Drugs 2007; 18: 389404.
  • 49
    Matthew EM,Yen TJ,Dicker DT,Dorsey JF,Yang W,Navaraj A,El-Deiry WS. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007; 6: 25712578.
  • 50
    Freeman H,Shimomura K,Cox RD,Ashcroft FM. Nicotinamide nucleotide transhydrogenase: A link between insulin secretion, glucose metabolism and oxidative stress. Biochem Soc Trans 2006; 34(Part 5): 806810.
  • 51
    Vasiliou V,Pappa A,Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact 2000; 129: 119.
  • 52
    Loo TW,Bartlett MC,Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharmacol 2004; 1: 426433.
  • 53
    Pajic M,Iyer JK,Kersbergen A,van der Burg E,Nygren AO,Jonkers J,Borst P,Rottenberg S. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res 2009; 69: 63966404.
  • 54
    Fox ME,Smith PJ. Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmacol 1995; 35: 403410.
  • 55
    Takagi K,Dexheimer TS,Redon C,Sordet O,Agama K,Lavielle G,Pierre A,Bates SE,Pommier Y. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther 2007; 6(12 Part 1): 32293238.
  • 56
    Lagas JS,Sparidans RW,van Waterschoot RA,Wagenaar E,Beijnen JH,Schinkel AH. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob Agents Chemother 2008; 52: 10341039.
  • 57
    Gupta PB,Onder TT,Jiang G,Tao K,Kuperwasser C,Weinberg RA,Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645659.